Californian antibody specialist Electra Therapeutics has appointed Kathy Dong as president and chief executive, replacing current CEO Adam Rosenthal.
Dr Rosenthal remains chief executive of Star Therapeutics, the company that spun out Electra, and will also remain as a board member at Electra.
Formerly chief operating officer at Star, Dr Dong (pictured) has more than 15 years of experience in corporate development, business operations, portfolio management, and product commercialization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze